See more : Core Scientific, Inc. (CORZ) Income Statement Analysis – Financial Results
Complete financial analysis of Medigen Vaccine Biologics Corporation (6547.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medigen Vaccine Biologics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Taiwan Takisawa Technology Co., Ltd. (6609.TWO) Income Statement Analysis – Financial Results
- Meryllion Resources Corp. (MYR.CN) Income Statement Analysis – Financial Results
- iRhythm Technologies, Inc. (IRTC) Income Statement Analysis – Financial Results
- Agilysys, Inc. (AGYS) Income Statement Analysis – Financial Results
- Applied Minerals, Inc. (AMNL) Income Statement Analysis – Financial Results
Medigen Vaccine Biologics Corporation (6547.TWO)
About Medigen Vaccine Biologics Corporation
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 389.62M | 365.04M | 3.28B | 11.51M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 159.40M | 577.64M | 975.96M | 3.87M | 0.00 | 101.02M | 82.81M | 19.18M | 12.80M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 230.22M | -212.60M | 2.31B | 7.64M | 1.12M | -101.02M | -82.81M | -19.18M | -12.80M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 59.09% | -58.24% | 70.25% | 66.36% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.20B | 1.14B | 1.19B | 679.56M | 538.73M | 396.98M | 287.20M | 177.18M | 157.15M | 88.42M | 75.25M | 21.84M |
| General & Administrative | 86.49M | 110.84M | 140.71M | 84.31M | 66.30M | 69.36M | 48.84M | 42.40M | 26.08M | 19.93M | 1.46M | 166.00K |
| Selling & Marketing | 156.94M | 72.83M | 7.50M | 7.65M | 0.00 | 0.00 | 0.00 | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 243.44M | 183.67M | 148.21M | 91.96M | 66.30M | 69.36M | 48.84M | 42.40M | 26.08M | 19.93M | 1.46M | 166.00K |
| Other Expenses | 0.00 | 80.98M | 449.80M | 104.54M | 5.32M | 313.00K | 2.58M | 12.09M | 2.11M | 2.94M | 0.00 | 0.00 |
| Operating Expenses | 1.44B | 1.32B | 1.34B | 771.52M | 605.03M | 466.34M | 336.04M | 219.58M | 183.23M | 108.35M | 76.71M | 22.01M |
| Cost & Expenses | 1.60B | 1.90B | 2.32B | 775.39M | 605.03M | 466.34M | 336.04M | 219.58M | 183.23M | 108.35M | 76.71M | 22.01M |
| Interest Income | 83.28M | 7.61M | 2.74M | 1.48M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 5.00K |
| Interest Expense | 37.57M | 26.89M | 6.02M | 16.42M | 19.13M | 10.32M | 6.83M | 2.10M | 606.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 131.17M | 127.89M | 112.54M | 122.25M | 118.48M | 101.02M | 82.81M | 19.18M | 12.80M | 11.63M | 9.02M | 1.29M |
| EBITDA | -991.09M | -1.32B | 1.53B | -535.61M | -480.11M | -365.00M | -250.64M | -188.31M | -168.32M | -93.78M | -67.79M | -20.72M |
| EBITDA Ratio | -254.37% | -361.55% | 46.60% | -4,654.62% | -42,866.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.21B | -1.45B | 1.42B | -657.86M | -598.59M | -466.34M | -336.04M | -219.58M | -183.23M | -108.35M | -76.71M | -22.01M |
| Operating Income Ratio | -311.54% | -396.58% | 43.17% | -5,717.05% | -53,445.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 53.99M | 61.69M | 446.53M | 89.60M | -13.81M | -10.00M | -4.25M | 10.00M | 1.50M | 2.94M | -95.00K | 5.00K |
| Income Before Tax | -1.16B | -1.47B | 1.41B | -674.28M | -617.72M | -476.34M | -340.29M | -209.58M | -181.73M | -105.41M | -76.80M | -22.00M |
| Income Before Tax Ratio | -297.68% | -403.95% | 42.98% | -5,859.74% | -55,153.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 26.89M | 6.02M | 16.42M | 19.13M | 313.00K | 2.58M | 12.09M | 2.11M | 2.94M | 176.00K | 0.00 |
| Net Income | -1.16B | -1.50B | 1.41B | -690.70M | -636.84M | -476.34M | -340.29M | -209.58M | -181.73M | -105.41M | -76.80M | -22.00M |
| Net Income Ratio | -297.68% | -411.31% | 42.98% | -6,002.42% | -56,861.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.53 | -4.64 | 4.47 | -2.48 | -2.69 | -2.14 | -1.72 | -1.24 | -1.34 | -1.04 | -3.14 | -2.67 |
| EPS Diluted | -3.53 | -4.64 | 4.42 | -2.48 | -2.69 | -2.09 | -1.72 | -1.20 | -1.29 | -1.04 | -3.14 | -2.67 |
| Weighted Avg Shares Out | 328.57M | 323.48M | 315.53M | 278.28M | 236.57M | 222.79M | 197.64M | 169.34M | 135.48M | 101.21M | 24.45M | 8.25M |
| Weighted Avg Shares Out (Dil) | 328.32M | 323.48M | 319.11M | 278.28M | 236.57M | 228.26M | 197.64M | 174.97M | 141.36M | 101.21M | 24.45M | 8.25M |
Source: https://incomestatements.info
Category: Stock Reports